找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Information Technologies in Medicine; 5th International Co Ewa Pi?tka,Pawel Badura,Wojciech Wieclawek Conference proceedings 2016 Springer

[復(fù)制鏈接]
樓主: Clientele
31#
發(fā)表于 2025-3-26 22:37:19 | 只看該作者
32#
發(fā)表于 2025-3-27 04:43:30 | 只看該作者
33#
發(fā)表于 2025-3-27 06:54:12 | 只看該作者
Prediction of Newborn Weight Using Questionnaire Data and Machine Learning Approach infancy and childhood. Low birth weight is a multifaceted public health problem. The prevalence of this diagnosis is estimated to be 15–20?% worldwide (more than 20 million infants) and occurs mostly in developing countries (95.6?%). There are many factors, which affect the birth weight of newborns
34#
發(fā)表于 2025-3-27 12:41:12 | 只看該作者
35#
發(fā)表于 2025-3-27 13:35:44 | 只看該作者
Machine Learning Can Reliably Distinguish Histological Patterns of Micropapillary and Solid Lung Adeal quantification of lung tumor composition is very time consuming, but it can potentially be aided by a machine learning application. We have updated our previously developed methodology to segment and distinguish solid and micropapillary lung tumor subtypes. Binary tumor masks delineated by machin
36#
發(fā)表于 2025-3-27 18:28:03 | 只看該作者
37#
發(fā)表于 2025-3-27 23:26:40 | 只看該作者
38#
發(fā)表于 2025-3-28 02:58:29 | 只看該作者
Georg Aumayructs have been approved over the past several years including Rituxan, Remicade, Avastin, Humira, and Herceptin. In addition, over 300 new drugs are currently in clinical trials. With both large, established biotechnology companies and small start-ups involved in the development of this important cl
39#
發(fā)表于 2025-3-28 08:36:13 | 只看該作者
40#
發(fā)表于 2025-3-28 14:01:33 | 只看該作者
Kimiaki Shirahama,Marcin Grzegorzekntibodies products will become increasingly prevalent over t.Monoclonal antibodies represent one of the fastest growing areas of new drug development within the pharmaceutical industry. Several blockbuster products have been approved over the past several years including Rituxan, Remicade, Avastin,
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-23 01:28
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
青神县| 榆树市| 盐山县| 南江县| 辉县市| 华宁县| 利辛县| 承德县| 武夷山市| 攀枝花市| 永城市| 六安市| 县级市| 普安县| 隆尧县| 科尔| 乌恰县| 永城市| 合作市| 彩票| 左贡县| 孝感市| 炎陵县| 通海县| 白水县| 会泽县| 辽宁省| 法库县| 康定县| 泽库县| 疏勒县| 井冈山市| 大荔县| 新和县| 安宁市| 涡阳县| 通海县| 射阳县| 襄垣县| 深水埗区| 毕节市|